A5029993254- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- CAR-T cell therapy research
- Acute Lymphoblastic Leukemia research
- Integrated Circuits and Semiconductor Failure Analysis
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Neutropenia and Cancer Infections
- Silicon Carbide Semiconductor Technologies
- Chronic Lymphocytic Leukemia Research
- Cancer Genomics and Diagnostics
- Lymphoma Diagnosis and Treatment
- Oral health in cancer treatment
- Head and Neck Cancer Studies
- Mycobacterium research and diagnosis
- Multiple Myeloma Research and Treatments
- Salivary Gland Disorders and Functions
- Immunodeficiency and Autoimmune Disorders
- Renal Transplantation Outcomes and Treatments
- Gut microbiota and health
- Immune Cell Function and Interaction
- Clostridium difficile and Clostridium perfringens research
- T-cell and B-cell Immunology
- Prenatal Screening and Diagnostics
- Virus-based gene therapy research
Cornell University
2023-2025
Weill Cornell Medicine
2023-2025
New York Hospital Queens
2023-2024
Presbyterian Hospital
2023-2024
NewYork–Presbyterian Hospital
2023-2024
Memorial Sloan Kettering Cancer Center
2024
Hartford Financial Services (United States)
2022-2023
Hartford Hospital
2022-2023
Tel Aviv University
2016-2022
UConn Health
2019-2022
Abstract Treatment of chronic lymphocytic leukemia (CLL) has shifted from chemo-immunotherapy to targeted agents. To define the evolutionary dynamics induced by therapy in CLL, we perform serial exome and transcriptome sequencing for 61 ibrutinib-treated CLLs. Here, report clonal shifts (change >0.1 cancer cell fraction, Q < 0.1) 31% patients during first year therapy, associated with adverse outcome. We also observe transcriptional downregulation pathways mediating energy metabolism,...
Tumor-intrinsic features may render large B-cell lymphoma (LBCL) insensitive to CD19-directed chimeric antigen receptor T cells (CAR-T). We hypothesized that TP53 genomic alterations are detrimental response outcomes in LBCL treated with CD19-CAR-T.Patients CD19-CAR-T were included. Targeted next-generation sequencing was performed on pre-CAR-T tumor samples a subset of patients. Response and survival rates by histologic, cytogenetic, molecular assessed. Within cohort newly diagnosed...
Abstract Clinical decisions in allogeneic hematopoietic stem cell transplantation (allo-HSCT) are supported by the use of prognostic scores for outcome prediction. Scores vary their features and composition development cohorts. We sought to externally validate compare performance 8 commonly applied scoring systems on a cohort allo-HSCT recipients. Among 528 patients studied, acute myeloid leukemia was leading transplant indication (44%) 46% had matched sibling donor. Most models successfully...
Optimizing natural killer (NK) cell alloreactivity could further improve outcome after allogeneic hematopoietic transplantation (alloHCT). The donor’s Killer-cell Immunoglobulin-like Receptor (KIR) genotype may provide important information in this regard. In the past decade, different models have been proposed aiming at maximizing NK activation by activating KIR-ligand interactions or minimizing inhibitory interactions. Alternative classifications intended predicting alloHCT donor...
Abstract Oral mucositis (OM) is a common debilitating dose-limiting toxicity of cancer treatment, including hematopoietic stem cell transplantation (HSCT). We hypothesized that the oral microbiome disturbed during allogeneic HSCT, partially accounting for variability in OM severity. Using 16S ribosomal RNA gene sequence analysis, metabolomic profiling, and computational methods, we characterized behavior salivary metabolome 184 patients pre- post-HSCT. Transplantation was associated with...
B-cell maturation antigen (BCMA)-targeting chimeric receptor T cells (CAR-Ts) used in multiple myeloma (MM) are rapidly becoming a mainstay the treatment of relapsed/refractory (R/R) disease, and CAR-T expansion after infusion has been shown to inform depth duration response (DoR), but measuring this process remains investigational. This multicenter study describes kinetics prognostic impact absolute lymphocyte count (ALC) first 15 days 156 patients with relapsed MM treated BCMA-targeting...
Abstract Background Oral mucositis (OM) is a common toxicity of stem cell transplantation (SCT). We sought to evaluate OM burden, risk factors, and implications in cohort allogeneic‐SCT recipients. Methods This was single‐center study including 115 adult transplanted between 2016 2018 for various hematological conditions. Conditioning intensity categorized as myeloablative (MAC, 39%), reduced (34%), or (RTC, 27%) patients conditioned with fludarabine‐treosulfan. prospectively graded using...
Anti CD19 chimeric antigen receptor (CAR) T-cell therapy has transformed the care of relapsed and refractory aggressive B-cell lymphoma. However, financial toxicity manufacturing time represent barriers to its widespread implementation. Study applicability, toxicity, efficacy a locally produced autologous CD19-directed CAR product were studied. We performed phase 1b/2 clinical trial with point-of-care (POC) that contains CD28 costimulatory domain. Adult patients lymphoma or low-grade who...
Disease progression is a substantial challenge in patients with non-Hodgkin lymphoma (NHL) undergoing chimeric antigen receptor T cell (CAR-T) therapy. Here we present InflaMix (INFLAmmation MIXture Model), an unsupervised quantitative model integrating 14 pre-CAR-T infusion laboratory and cytokine measures capturing inflammation end-organ function. Developed using cohort of 149 NHL, revealed inflammatory signature associated high risk CAR-T treatment failure, including increased hazard...
Predictive models may help in determining the risk/benefit ratio of allogeneic hematopoietic stem cell transplantation (HSCT) acute leukemia (AL). Using a machine-learning algorithm we have previously developed AL- European Society for Blood and Marrow Transplantation (EBMT) score prediction mortality following transplantation. We report here first external validation AL-EBMT cohort AL patients from Italian national network. A total 1848 transplanted between years 2000-2014 were analyzed....
Individual comorbidities have distinct contributions to nonrelapse mortality (NRM) following allogeneic hematopoietic cell transplantation (allo-HCT). We studied the impact of individually and in combination a single-center cohort 573 adult patients who underwent CD34-selected allo-HCT myeloablative conditioning. Pulmonary disease, moderate severe hepatic comorbidity, cardiac disease any type, renal dysfunction were associated with increased NRM multivariable Cox regression models. A...
Summary Recent reports have raised concerns about the association of chimeric antigen receptor T cell (CAR‐T) with non‐negligible cardiotoxicity, particularly atrial arrhythmias. First, we conducted a pharmacovigilance study to assess reporting arrhythmias following CD19‐directed CAR‐T. Subsequently, determine incidence, risk factors and outcomes post‐CAR‐T, compiled retrospective single‐centre cohort non‐Hodgkin lymphoma patients. Only commercial CAR‐T products were considered. Atrial...
Purpose: Survival of acute leukemia (AL) patients following umbilical cord blood transplantation (UCBT) is dependent on an array individual features. Integrative models for risk assessment are lacking. We sought to develop a scoring system prediction overall survival (OS) and leukemia-free (LFS) at 2 years UCBT in AL patients.Experimental Design: The study cohort included 3,140 pediatric adult from the European Society Blood Marrow Transplantation Eurocord registries. Patients received...